Chiara Biosciences is creating a new category of targeted protein degraders with its proprietary CURE-PRO™ platform, which uses a “puzzle-piece” approach to overcome the size and geometry limitations of first-generation degraders. The platform enables oral delivery, CNS penetration, and the rapid discovery of novel degrader pairs. Chiara’s unique combinatorial strategy supports a high throughput, reusable platform for developing both an internal pipeline and collaborative solutions for strategic CURE-PRO development.
